# Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies

> **NCT06135584** · NA · NOT_YET_RECRUITING · sponsor: **The Affiliated Hospital of Hangzhou Normal University** · enrollment: 1000 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Fatty Liver Disease
- Cirrhosis

## Interventions

- **DRUG:** Pioglitazone metformin tablets
- **DRUG:** Other drugs
- **OTHER:** Drug-free

## Key facts

- **NCT ID:** NCT06135584
- **Lead sponsor:** The Affiliated Hospital of Hangzhou Normal University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-18
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06135584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06135584, "Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06135584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*